Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;24(5):379-389.
doi: 10.1007/s11883-022-01013-x. Epub 2022 Mar 28.

The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia

Waleed Z Butt  1   2 , Jennifer K Yee  3   4
Affiliations
Review

The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia

Waleed Z Butt et al. Curr Atheroscler Rep. 2022 May.

Abstract

Purpose of review: Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy.

Recent findings: Ezetimibe is commonly used as second-line pharmacotherapy for treatment of HeFH and HoFH. Colesevelam, a bile acid sequestrant, may be considered for adjunct therapy. Since 2015, the PCSK9 inhibitor evolocumab has been available for adolescents, and its FDA approval has now expanded to age 10 years. The ANGPTL3 inhibitor evinacumab has been approved for children age 12 years and older. A clinical trial for lomitapide is in progress. Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.

Keywords: Children; Cholesterol; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Low-density lipoprotein; Pediatrics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. - PubMed - PMC - DOI
    1. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–6. - PubMed - DOI
    1. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP III, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adultsimplications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA. 1999;281(8):727–35. - PubMed - DOI
    1. Perak AM, Ning H, Kit BK, de Ferranti SD, Van Horn LV, Wilkins JT, et al. Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999–2016. JAMA. 2019;321(19):1895–905. - PubMed - PMC - DOI
    1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52(7):1544–68. - PubMed - PMC - DOI

LinkOut - more resources